睿知中国医院研究地图
候选清单

正在招募食管鳞状细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 3 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 3

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  2. 研究中心上海交通大学医学院附属仁济医院Renji Hospital上海医院页面
  3. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06465069,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.

    入选标准第 7 条

    Cohorts A1/A2/C/D: prior treatment with enfortumab vedotin is allowed, but not required

    入选标准第 10 条

  3. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    入选标准第 16 条

  4. Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)

    入选标准第 14 条

  5. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

    排除标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);化验:血常规、肝肾功能;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06465069,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Have one of the following solid tumor cancers:
  2. Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer
  3. Cohort A2/B/D: urothelial carcinoma
  4. Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, HNSCC (head and neck squamous cell carcinoma), esophageal cancer, pancreatic cancer, or prostate cancer
  5. Prior Systemic Therapy Criteria:
  6. Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies
  7. Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.
  8. Cohort D: Treatment-naive for locally advanced or metastatic urothelial cancer.
  9. Prior enfortumab vedotin specific requirements:
  10. Cohorts A1/A2/C/D: prior treatment with enfortumab vedotin is allowed, but not required
  11. Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting
  12. Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.
  13. Measurability of disease
  14. Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)
  15. Measurable disease is required as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) for all Cohorts. Cohort A1 may permit non-measurable disease as defined by RECIST v1.1
  16. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  17. Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations

排除标准:Exclusion Criteria:

  1. Individual with known or suspected uncontrolled CNS metastases
  2. Individual with uncontrolled hypercalcemia
  3. Individual with uncontrolled diabetes
  4. Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant
  5. Any serious unresolved toxicities from prior therapy
  6. Significant cardiovascular disease
  7. Recent thromboembolic event and/or clinically significant bleeding disorder
  8. Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 ms
  9. History of pneumonitis/interstitial lung disease
  10. History of Grade ≥3 skin toxicity associated with enfortumab vedotin that required treatment discontinuation
  11. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

引自 ClinicalTrials.gov, NCT06465069, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06465069,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06465069